Introduction
When preparing a regulatory submission, one of the most critical components is the Integrated Safety Summary (ISS). Far from being a simple aggregation of safety data, the ISS is a detailed and carefully constructed analysis that provides regulators with a complete picture of a product’s safety profile across clinical trials. This blog explores what an ISS is and how sponsors can prepare for the challenges that often arise in its delivery.
What is an ISS?
The ISS is a comprehensive analysis of patient safety data across clinical trials included in a drug development program. [1] It consolidates adverse event reporting, laboratory findings, vital signs, and other safety endpoints into a single, consistent, and regulator-ready package. Unlike study-level safety analyses, the ISS provides a global view, revealing patterns or risks that might not be visible within individual studies.
Why is the ISS so important?
Regulators rely on the ISS to understand not just whether a treatment works, but whether it can be used safely in real-world settings. A strong ISS helps demonstrate that safety data has been collected, analyzed, and presented in a way that supports benefit–risk evaluation.
Challenges sponsors face include:
- Data integration across trials: Different study designs, database structures, and standards often create barriers.
- Evolving SAPs: Regulatory feedback and shifting priorities can require frequent updates.
- Timelines: ISS work often begins late in development, leaving little room for error.
- Data consistency: Ensuring that data from multiple sources align is critical for credibility.
How to effectively prepare for successful ISS submissions
Engaging experts for ISS development is essential, as these high-level regulatory documents demand advanced expertise. [2] Sponsors that plan early, standardize data formats, and secure experienced statistical programming support can avoid costly delays and ensure quality.
- Engaging specialist, data-focused CROs is often the most effective way to navigate these challenges. These providers have deep experience in integrating complex datasets, managing evolving SAPs, and ensuring regulatory compliance.
- Sponsors that plan early, standardize data formats, and secure experienced statistical programming support can avoid costly delays and ensure quality.
- Working with a specialist provider not only mitigates risks but also ensures efficient, high-quality outputs—allowing sponsors to focus on strategic decision-making rather than the intricacies of data management.
Conclusion
An ISS is more than just a regulatory requirement—it is the foundation of a safe and successful submission. By anticipating challenges and leveraging specialist expertise, sponsors can deliver high-quality ISS packages that withstand regulatory scrutiny.
2. Fissekis, J.A. (2009). Integrated summaries of safety and efficacy. In: Wood, L.F., Foote, M. (eds) Targeted Regulatory Writing Techniques: Clinical Documents for Drugs and Biologics. Birkhäuser, Basel. https://doi.org/10.1007/978-3-7643-8362-6_9
